GlaxoSmithKline (GSK) will support Cancer Research UK's Cambridge Research Institute (CRI), and Cancer Research Technology (CRT) in researching a treatment for kidney, bowel and pancreatic cancer.
CRT, the Cancer Research UK-owned commercialisation and development company, has secured a deal with GSK that will make use of the charity's expertise to carry out two projects.
The first project seeks to understand how the compound GSK2136773, containing the active portion of an antibody, works in laboratory models of pancreatic cancer.
The second project will use imaging techniques to compare the antibody's effectiveness against current therapies used in treating bowel and kidney cancer.
